Last reviewed · How we verify
REFRESH LIQUIGEL®
REFRESH Liquigel provides ocular lubrication and protection by forming a viscous gel layer on the corneal surface to relieve dry eye symptoms.
REFRESH Liquigel provides ocular lubrication and protection by forming a viscous gel layer on the corneal surface to relieve dry eye symptoms. Used for Dry eye syndrome / keratoconjunctivitis sicca.
At a glance
| Generic name | REFRESH LIQUIGEL® |
|---|---|
| Sponsor | Allergan |
| Drug class | Artificial tear / ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The product is a lubricating eye gel containing carboxymethylcellulose sodium as its active ingredient. It adheres to the ocular surface and provides prolonged moisture retention, reducing friction and protecting the cornea and conjunctiva from irritation associated with dry eye disease. The gel formulation allows for extended contact time compared to aqueous solutions.
Approved indications
- Dry eye syndrome / keratoconjunctivitis sicca
Common side effects
- Blurred vision
- Eye irritation or discomfort
- Mild stinging upon instillation
Key clinical trials
- Cabozantinib for Patients With Recurrent or Progressive Meningioma (PHASE2)
- Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old (PHASE3)
- Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (PHASE1, PHASE2)
- INSTI's For The Management of HIV-associated TB (PHASE2)
- PLLA and CaHA-R for Aesthetic Rejuvenation (PHASE4)
- Efficacy and Safety of Ionized Atelocollagen Adhesion Barrier (Collabarrier®) in Spine Surgery (NA)
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (PHASE4)
- Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REFRESH LIQUIGEL® CI brief — competitive landscape report
- REFRESH LIQUIGEL® updates RSS · CI watch RSS
- Allergan portfolio CI